Sign In
NewsRadar

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.

   


XOMA and Affimed Sign Antibody Cross-License and Collaboration Agreement


Berkeley, CA and Heidelberg, Germany - October 2, 2006 - XOMA Ltd. (Nasdaq: XOMA) and Affimed Therapeutics AG announced today that they have signed a cross-license and collaboration agreement for antibody-related technologies. Financial terms were not disclosed.

The agreement provides XOMA with a license under Affimed's antibody library patents for antibody discovery purposes, as well as for the development and commercialization of antibodies. In addition, Affimed has agreed to build two customized patient-derived human antibody phage display libraries according to XOMA specifications.

The agreement provides Affimed with a license to use XOMA's Bacterial Cell Expression (BCE) technology for research purposes, with an option to acquire a BCE license for production and commercialization of antibodies, in particular for Affimed's proprietary TandAb and Flexibody technologies. XOMA also has agreed to provide Affimed with cell line development and process development services specific to a TandAb therapeutic product candidate that Affimed is currently developing.

'Affimed's custom libraries represent a powerful addition to XOMA's existing collection of the seven leading commercial human antibody phage display libraries. The advantage of patient-derived libraries is their potential to contain unique antibody candidates for the therapeutic area of interest,' said Jack Castello, chairman of the board, president and chief executive officer of XOMA. 'This collaboration extends XOMA's leadership in therapeutic antibodies, providing a single point of access to an even broader fully-integrated antibody discovery and development platform.'

'We are delighted to enter into this broad cross-license and collaboration agreement with XOMA' said Rolf H. Günther MD PhD, chief executive officer of Affimed. 'The access to XOMA's state-of-the-art BCE technology represents another very important milestone for Affimed and provides new opportunities for the development of Affimed's promising recombinant antibody products. In addition to having the rights to use this technology in our development work, we are particularly pleased to have the benefit of XOMA's expertise in the development of cell lines and production systems for our TandAb therapeutic candidate.'


Further Information:
FOR XOMA Ltd.
Paul Goodson
Sr. Director, Investor Relations
goodson@xoma.com
(510) 204-7270

FOR AFFIMED THERAPEUTICS AG:
Dr. Douglas Pretsell
Account Director, Munich Bureau Chief
Northbank Communications
t : +49 (0)89 57 00 18 06
e: d.pretsell@northbankcommunications.com


About Affimed Therapeutics AG
Affimed is a private biopharmaceutical company based in Heidelberg, Germany and specializing in the development of recombinant antibodies - the fastest growing segment of the pharmaceutical industry. Affimed was founded in May of 2000 by Professor Melvyn Little as a spin-off of his group »Recombinant Antibodies« at the German Cancer Research Centre in Heidelberg.

The strength of Affimed's discovery platform lies in three large distinct antibody libraries that are the source of antibody leads which can be produced in a variety of formats from scFv, diabodies, full length antibodies to proprietary tetravalent formats such as Affimed's TandAb or Flexibody.

Affimed's existing pipeline comprises several very novel antibody formats targeting some potentially very high value cancer targets. Two cancer products are in advanced pre-clinical development. To learn more about Affimed, please visit www.affimed.com


About XOMA and its Bacterial Cell Expression Technology
XOMA is a leader in the discovery, development and manufacture of therapeutic antibodies, with a therapeutic focus that includes cancer and immune diseases. XOMA has royalty interests in RAPTIVA® (efalizumab), a monoclonal antibody product marketed worldwide (by Genentech, Inc. and Serono, SA) to treat moderate-to-severe plaque psoriasis, and LUCENTIS(tm)<


Publisher Contact Information:

Affimed Therapeutics
+49 (0)89 57 00 18 06
d.pretsell@northbankcommunications.com

Company profile of Affimed Therapeutics AG
Past press releases of Affimed Therapeutics AG.

Data


26,127
Tech investments
From our Online Data Service
16,882
VC-backed companies
From our Radar


Recent Deals


DATEAMOUNTSECTOR
Sep 13N/AEnergy related
Sep 13€12.6MConsumer electronics
Sep 12€39.0MBiopharmaceuticals
Sep 12€2.3MInternet commerce
Sep 12€2.1MInternet services
Sep 12€4.0MMedical devices
Sep 12€9.0MSoftware development

For information on Europe's most extensive database on technology funding click here!

Events



Press Releases


May 28
Identiq
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
Nethone
nethone raised over $1 million from innovation nest

Oct 1
The Link App
the link app launches version 2.0

Mar 29
Addex Therapeutics
addex sucessfully raises chf40 million in capital increase

Jan 2
Urban Jungle
urban jungle raises £1m in seed funding to build tech-enabled home ...





About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.